Argenx SE: UBS raises its recommendation to Buy

argenx (ARGX) reported positive Phase 3 trial results for VYVGART Hytrulo in treating autoimmune myositis. Shares have surged, with a 1-year return of 50.58%. Analysts debate valuation, with some calling it 32.2% overvalued at €907.40, while others see a 52.2% discount. Investors should watch for clinical setbacks and pricing pressures.

UBS upgraded Argenx (ARGX) to 'Buy' with a $1,400 price target, citing strong Vyvgart franchise prospects and potential $20B peak sales. ARGX shares are up over 50% YTD. UBS also noted the company's expanding pipeline, including empasiprubart, addressing concerns about reliance on Vyvgart.

UBS upgraded argenx SE (ARGX) to Buy with a $1,400 price target, citing positive trial results for Vyvgart. ARGX's stock is trading at $1,048.84, 29.0% below its GF Value™ of $1,478.00. The company has a GF Score™ of 78, strong financial health, and a growing pipeline. Institutional interest remains high, with 8 gurus holding shares.

UBS upgraded argenx SE (ARGX) to Buy from Neutral, raising its 12-month price target to $1,400 from $960. The firm projects a $20B peak sales opportunity for the company's flagship product, Vyvgart.

argenx (ARGX) reported positive Phase III results for efgartigimod in treating autoimmune myositis, with a 15.4-point improvement in TIS over placebo. The company's shares rose 8% to 789 euros.

UBS upgraded Argenx (ARGX) to Buy with a $1,400 price target, citing Vyvgart's potential for $18B peak sales and a strong pipeline. The stock rose 2.8% in Brussels. Analyst Xian Deng highlighted better-than-expected Phase 3 data and underappreciated pipeline assets, including empasiprubart and a recent $2B acquisition.